Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00006205-200502000-00010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use.
Am J Drug Alcohol Abuse
January 2025
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kratom is a plant with alkaloids acting at opioid, serotonergic, adrenergic, and other receptors. Consumers report numerous use motivations. To distinguish subgroups of kratom consumers by kratom-use motivations using latent-class analysis.
View Article and Find Full Text PDFExamining how support persons' buprenorphine attitudes and their communication about substance use impacts patient well-being.
Am J Drug Alcohol Abuse
January 2025
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
While social support benefits those in treatment for opioid use disorder, it is unclear how social support impacts patient outcomes. This study examines how support person attitudes toward buprenorphine and their communication about substance use are associated with the well-being of patients receiving buprenorphine treatment. We analyzed cross-sectional baseline data from 219 buprenorphine patients (40% female) and their support persons (72% female).
View Article and Find Full Text PDFA case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period.
Clin Toxicol (Phila)
January 2025
National Poisons Information Service, Cardiff Unit, University Hospital Llandough, Penarth, UK.
Introduction: Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub . It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use.
Methods: A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed.
Is there a risk of esketamine misuse in clinical practice?
Ther Adv Drug Saf
January 2025
Pharmacology Department, School of Medicine, University of Valladolid, Valladolid, Spain.
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years.
View Article and Find Full Text PDFSystemic bupropion treatment reduces long-access cocaine self-administration in male and female rats.
J Psychopharmacol
January 2025
Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Background: More than 1 million people in the United States meet the criteria for cocaine use disorder (CUD), and over 19,000 people died from cocaine-related overdoses in 2020, but there are currently no FDA-approved medications for the treatment of CUD. Bupropion is an antidepressant currently prescribed to treat depression and nicotine addiction that acts by inhibiting norepinephrine and dopamine transporters.
Methods: In this study, we tested the effect of several doses of systemic bupropion on cocaine self-administration in male and female Wistar rats.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!